Definium Therapeutics posts Phase 3 Voyage topline results presentation

Definium Therapeutics published a Phase 3 Voyage topline results presentation for DT120 ODT in generalized anxiety disorder.

• Primary endpoint met, showing a 5.4-point HAM-A improvement versus placebo at week 12; p<0.0001; effect size 0.81.
• Rapid separation reported, including a 7.7-point HAM-A improvement versus placebo at week 1; p<0.0001.
• Safety through week 12 described as generally well tolerated; no new safety signals; no serious adverse events in the DT120 arm.
• Trial enrolled 214 participants, randomized 1:1 to a single 100 microgram dose of DT120 ODT or placebo in a 12-week double-blind period.